TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Ahmad Masri, MD, MS
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Amy Mottl, MD, MPH
Prof. Christoph Wanner
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
Muthiah Vaduganathan, MD, MPH
Anuradha Lala-Trindade, MD
Brendon Neuen, MBBS, PhD
The CONFIDENCE Trial: Data Insights
prof. Hiddo Heerspink
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
Jennifer B. Green, MD
Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
APOC3 Inhibition: New Frontiers Managing Patients with FCS & SHTG
Daniel Gaudet, MD, PhD
Pam R. Taub, MD, FACC, FASPC
SHTG: Defining the Unmet Clinical Need
Remnant Cholesterol: The Missing Link in ASCVD risk
Targeting Mixed Hyperlipidemia with APOC3 Inhibition
Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
Riccardo Maria Inciardi, MD, PhD
Cristina Gavina, MD, PhD
Giuseppe Galati, MD
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Akshay S. Desai, MD
FINE-HEART Pooled Analysis
Maria Pabon
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
John Ostrominski
Echo essentials for HCM: The heartbeat of diagnosis and treatment
Thor Edvardsen, MD, PhD
Maurizio Pieroni, MD, PhD
Elena Arbelo, MD, PhD
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.